Premium
Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax ( HMA‐Ven ) or liposomal daunorubicin‐cytarabine ( CPX ‐351)
Author(s) -
Salhotra Amandeep,
Aribi Ahmed,
Ngo Dat,
Zhang Jianying,
Sandhu Karamjeet,
AlMalki Monzr,
Ali Haris,
Koller Paul,
Arslan Shukaib,
Budde Elizabeth,
Khaled Samer,
Dadwal Sanjeet,
Snyder David S.,
Artz Andrew,
Forman Stephen,
Nakamura Ryotaro,
Stein Anthony,
Marcucci Guido,
Aldoss Ibrahim,
Pullarkat Vinod
Publication year - 2021
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.26157
Subject(s) - venetoclax , medicine , cytarabine , hypomethylating agent , regimen , population , oncology , chemotherapy regimen , leukemia , chemotherapy , gastroenterology , chronic lymphocytic leukemia , biology , biochemistry , gene expression , dna methylation , gene , environmental health